OPUS-1 success de-risks VAX-31's adult indication and supports BLA filing in H1 2028. Watch for OPUS-2/OPUS-3 results in H1 2027 and the infant Phase 2 data by end of H1 2027 for further validation. The two serotypes (3 and 12F) that missed the strict noninferiority threshold vs PCV21 but met the historical threshold may be a focus of FDA review but are unlikely to block approval given the overall robust dataset.
Price Chart
Executive Summary
Vaxcyte announced positive topline results from the OPUS-1 pivotal Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older, including noninferiority vs Prevnar 20 and/or Capvaxive on all shared serotypes and superiority on three unique serotypes plus cross-reactive serotype 20B, with a safety profile similar to comparators. The results support a planned BLA submission in the first half of 2028, positioning VAX-31 as a potential new standard-of-care with broader coverage than existing adult PCVs.
Key Facts
- VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50+; all 28 shared serotypes met noninferiority (LBCI >0.667).
- Three serotypes unique to VAX-31 and cross-reactive serotype 20B met superiority criterion (LBCI >2.0).
- Immunobridging endpoint met: all 321 serotype comparisons in adults 18-49 vs 50-64 passed noninferiority.
- Safety profile similar to PCV20 and PCV21; no related serious adverse events or discontinuations.
- Company expects to report OPUS-2 and OPUS-3 results in H1 2027, with BLA submission planned for H1 2028.
- VAX-31 is designed to cover ~95% of IPD and ~88% of pneumococcal pneumonia in U.S. adults 50+.
Financial Impact
Positive pivotal Phase 3 data for VAX-31, the broadest-spectrum PCV candidate in the clinic, supports a path to FDA approval. No financial figures provided in the release.
Risk Factors
- Serotypes 3 and 12F missed the prespecified noninferiority criterion (LBCI >0.667) vs PCV21, though met the historical >0.5 threshold.
- Regulatory review may focus on comparisons to PCV21 given its larger share of adult disease coverage.
- Manufacturing consistency study and infant data still required before BLA submission.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374299 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $70.65 $63.68 | ▲ +9.87% | ▲ +8.37% | $60.67 (+14.13%) |
Oct 8, 2026 19d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.67 (+15.00%) |
Oct 8, 2026 19d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.67 (+15.00%) |
Oct 5, 2026 22d ago | 424B5 | $66.70 $66.80 | ▲ +0.15% | ▲ +0.29% | $60.67 (−9.04%) |
Oct 5, 2026 22d ago | 424B5 | $66.70 $66.80 | ▼ −0.15% | ▼ −0.29% | $60.67 (+9.04%) |
Oct 5, 2026 22d ago | 8-K | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Oct 5, 2026 22d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Oct 4, 2026 23d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Aug 5, 2026 11w ago | Insider Cluster | $58.89 $58.86 | ▼ −0.05% | ▼ −1.26% | $60.67 (+3.02%) |
Jul 6, 2026 16w ago | Insider Cluster | $60.67 $56.21 | ▼ −7.35% | ▼ −7.90% | $60.67 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers